313 related articles for article (PubMed ID: 31550190)
1. Persistence with Basal-Bolus Insulin Therapy in Patients with Type 2 Diabetes Mellitus and Effect on Clinical and Economic Outcomes: A Retrospective Claims Database Study.
Edelman SV; Ermakova A; Xiong Y; Sieradzan R; Taylor SD
J Manag Care Spec Pharm; 2019 Dec; 25(12):1420-1431. PubMed ID: 31550190
[TBL] [Abstract][Full Text] [Related]
2. Effect of V-Go Versus Multiple Daily Injections on Glycemic Control, Insulin Use, and Diabetes Medication Costs Among Individuals with Type 2 Diabetes Mellitus.
Raval AD; Nguyen MH; Zhou S; Grabner M; Barron J; Quimbo R
J Manag Care Spec Pharm; 2019 Oct; 25(10):1111-1123. PubMed ID: 31556817
[TBL] [Abstract][Full Text] [Related]
3. Clinical and Economic Outcomes of Patients with Type 2 Diabetes on Multiple Daily Injections of Basal-bolus Insulin (MDI) Therapy: A Retrospective Cohort Study.
Brixner D; Ermakova A; Xiong Y; Sieradzan R; Sacks N; Cyr P; Taylor SD
Clin Ther; 2019 Feb; 41(2):303-313.e1. PubMed ID: 30709610
[TBL] [Abstract][Full Text] [Related]
4. Treatment persistence and adherence in people with type 2 diabetes switching to iGlarLixi vs free-dose combinations of basal insulin and glucagon-like peptide 1 receptor agonist.
Edelman S; Cassarino D; Kayne D; Dex T; Li X; Pasquel FJ
J Manag Care Spec Pharm; 2022 Sep; 28(9):958-968. PubMed ID: 36001104
[No Abstract] [Full Text] [Related]
5. Real-world persistence, adherence, health care resource utilization, and costs in people with type 2 diabetes switching from a first-generation basal insulin to a second-generation (insulin glargine 300 U/mL) vs an alternative first-generation basal insulin.
Wright EE; Malone DC; Trujillo JM; Gill J; Huse S; Li X; Zhou FL; Preblick R; Reid T
J Manag Care Spec Pharm; 2022 Jun; 28(6):592-603. PubMed ID: 35352995
[No Abstract] [Full Text] [Related]
6. Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Basal Insulin and Basal-Bolus Therapy in Patients with Type 2 Diabetes Based on Attainment of Clinically Relevant Treatment Targets.
Cannon AJ; Bargiota A; Billings L; Hunt B; Leiter LA; Malkin S; Mocarski M; Ranthe MF; Schiffman A; Doshi A
J Manag Care Spec Pharm; 2020 Feb; 26(2):143-153. PubMed ID: 31856636
[TBL] [Abstract][Full Text] [Related]
7. Demographic and Clinical Profiles of Type 2 Diabetes Mellitus Patients Initiating Canagliflozin Versus DPP-4 Inhibitors in a Large U.S. Managed Care Population.
Grabner M; Peng X; Geremakis C; Bae J
J Manag Care Spec Pharm; 2015 Dec; 21(12):1204-12. PubMed ID: 26679969
[TBL] [Abstract][Full Text] [Related]
8. Economic Impact of Treatment Duration and Persistence with Basal Insulin in Previously Insulin-Naive Users.
Kalirai S; Duan R; Liu D; Reed BL
J Manag Care Spec Pharm; 2017 Mar; 23(3):327-336. PubMed ID: 28230446
[TBL] [Abstract][Full Text] [Related]
9. Effect of Weight Change on Economic Outcomes Among Persons with Type 2 Diabetes Mellitus in the United States: Beyond Glycemic Control.
Karkare S; Fridman M; Dang-Tan T; Lu J; Smolarz BG; DeKoven M; Iyer NN
J Manag Care Spec Pharm; 2019 Jun; 25(6):658-668. PubMed ID: 30730232
[TBL] [Abstract][Full Text] [Related]
10. Health Outcomes Associated with Initiation of Basal Insulin After 1, 2, or ≥ 3 Oral Antidiabetes Drug(s) Among Managed Care Patients with Type 2 Diabetes.
Levin PA; Zhou S; Gill J; Wei W
J Manag Care Spec Pharm; 2015 Dec; 21(12):1172-81. PubMed ID: 26679966
[TBL] [Abstract][Full Text] [Related]
11. Factors Associated with Diabetes-Related Clinical Inertia in a Managed Care Population and Its Effect on Hemoglobin A1c Goal Attainment: A Claims-Based Analysis.
Ruiz-Negrón N; Wander C; McAdam-Marx C; Pesa J; Bailey RA; Bellows BK
J Manag Care Spec Pharm; 2019 Mar; 25(3):304-313. PubMed ID: 30816810
[TBL] [Abstract][Full Text] [Related]
12. Slow Titration and Delayed Intensification of Basal Insulin Among Patients with Type 2 Diabetes.
Mocarski M; Yeaw J; Divino V; DeKoven M; Guerrero G; Langer J; Thorsted BL
J Manag Care Spec Pharm; 2018 Apr; 24(4):390-400. PubMed ID: 29406841
[TBL] [Abstract][Full Text] [Related]
13. Influence of Treatment Intensification on A1c in Patients with Suboptimally Controlled Type 2 Diabetes After 2 Oral Antidiabetic Agents.
Kim K; Unni S; McAdam-Marx C; Thomas SM; Sterling KL; Olsen CJ; Johnstone B; Mitchell M; Brixner D
J Manag Care Spec Pharm; 2019 Mar; 25(3):314-322. PubMed ID: 30816811
[TBL] [Abstract][Full Text] [Related]
14. Impact of initiating insulin glargine disposable pen versus vial/syringe on real-world glycemic outcomes and persistence among patients with type 2 diabetes mellitus in a large managed care plan: a claims database analysis.
Xie L; Zhou S; Pinsky BW; Buysman EK; Baser O
Diabetes Technol Ther; 2014 Sep; 16(9):567-75. PubMed ID: 24735083
[TBL] [Abstract][Full Text] [Related]
15. Patient Support Program Increased Medication Adherence with Lower Total Health Care Costs Despite Increased Drug Spending.
Brixner D; Rubin DT; Mease P; Mittal M; Liu H; Davis M; Ganguli A; Fendrick AM
J Manag Care Spec Pharm; 2019 Jul; 25(7):770-779. PubMed ID: 31081461
[TBL] [Abstract][Full Text] [Related]
16. Basal insulin persistence, associated factors, and outcomes after treatment initiation among people with type 2 diabetes mellitus in the US.
Perez-Nieves M; Kabul S; Desai U; Ivanova JI; Kirson NY; Cummings AK; Birnbaum HG; Duan R; Cao D; Hadjiyianni I
Curr Med Res Opin; 2016; 32(4):669-80. PubMed ID: 26703951
[TBL] [Abstract][Full Text] [Related]
17. Clinical and economic outcomes among injection-naïve patients with type 2 diabetes initiating dulaglutide compared with basal insulin in a US real-world setting: the DISPEL Study.
Mody R; Huang Q; Yu M; Patel H; Zhang X; Wang L; Grabner M
BMJ Open Diabetes Res Care; 2019; 7(1):e000884. PubMed ID: 31875137
[TBL] [Abstract][Full Text] [Related]
18. Adherence, Persistence, and Health Care Costs for Patients Receiving Dipeptidyl Peptidase-4 Inhibitors.
Rascati KL; Worley K; Meah Y; Everhart D
J Manag Care Spec Pharm; 2017 Mar; 23(3):299-306. PubMed ID: 28230454
[TBL] [Abstract][Full Text] [Related]
19. Effect of Diabetes Treatment-Related Attributes on Costs to Type 2 Diabetes Patients in a Real-World Population.
Meng J; Casciano R; Lee YC; Stern L; Gultyaev D; Tong L; Kitio-Dschassi B
J Manag Care Spec Pharm; 2017 Apr; 23(4):446-452. PubMed ID: 28345434
[TBL] [Abstract][Full Text] [Related]
20. Impact of Out-of-Pocket Pharmacy Costs on Branded Medication Adherence Among Patients with Type 2 Diabetes.
Bibeau WS; Fu H; Taylor AD; Kwan AY
J Manag Care Spec Pharm; 2016 Nov; 22(11):1338-1347. PubMed ID: 27783549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]